Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.
Rachel Justus, PharmD, BCPS
Advertisement
Articles by Rachel Justus, PharmD, BCPS
Advertisement
Latest Updated Articles
The Role of PARP Inhibitors in Treating Ovarian CancerPublished: April 30th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
3
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
4
FDA Approves Gazyva for Active Lupus Nephritis
5
